Department of Neurosurgery, Bezmialem Vakif University Medical School, Vatan Street, Fatih, Istanbul, Turkey.
Department of Molecular Biology, Beykoz Institute of Life Sciences and Biotechnology, Bezmialem Vakif University, Yalikoy, Beykoz, Istanbul, Turkey.
Mol Biol Rep. 2024 Oct 3;51(1):1035. doi: 10.1007/s11033-024-09967-8.
Central nervous system lymphoma (CNSL) is a devastating disease with a poor prognosis. Early diagnosis, monitoring of the treatment response, and outcome prediction carry the utmost importance in the management of patients with CNSL. Surgical biopsy is the gold standard for tissue diagnosis, however, this procedure has potential complications. Therefore, there is a need for a method that provides information about diagnosis and patient monitoring to avoid surgical risks. The study aimed to investigate potential diagnostic biomarkers for patients with CNSL.
Patients with secondary CNSL were included in this study. Serum and cerebrospinal fluid (CSF) samples were collected before treatment and after completion of the treatment. Cell-free DNA (cfDNA), exosomes, free and exosomal microRNA (miR)-15a, miR-21, miR-155, miR-210, and miR-19b in both serum and CSF were examined, and they were compared with the controls. Also, their levels before and after treatment were compared. Nine patients with the diagnosis of secondary CNSL were reviewed. cfDNA, miR-15a, and miR-155 in serum, and exosome in CSF were found to be significantly higher in CNSL patients compared to the controls. Exosomal miR-15a, miR-21, miR-155, miR-210, and miR-19b in CSF were found to be significantly higher in CNSL patients compared to controls, whereas their levels in serum were not significantly high.
Our findings suggested that exosomes and exosomal miR-15a, miR-21, miR-155, miR-210 and miR-19b in CSF would be promising biomarkers for the diagnosis of patients with CNSL. Further studies are needed to confirm our findings.
中枢神经系统淋巴瘤（CNSL）是一种预后不良的毁灭性疾病。在 CNSL 患者的管理中，早期诊断、治疗反应监测和预后预测至关重要。手术活检是组织诊断的金标准，但该过程存在潜在并发症。因此，需要有一种方法可以提供有关诊断和患者监测的信息，以避免手术风险。本研究旨在探讨 CNSL 患者的潜在诊断生物标志物。
本研究纳入了继发性 CNSL 患者。在治疗前和治疗完成后采集血清和脑脊液（CSF）样本。检测血清和 CSF 中的游离 DNA（cfDNA）、外泌体、游离和外泌体 microRNA（miR）-15a、miR-21、miR-155、miR-210 和 miR-19b，并与对照组进行比较。还比较了治疗前后的水平。回顾了 9 名诊断为继发性 CNSL 的患者。与对照组相比，CNSL 患者的血清 cfDNA、miR-15a 和 miR-155 以及 CSF 中外泌体明显升高。与对照组相比，CSF 中外泌体 miR-15a、miR-21、miR-155、miR-210 和 miR-19b 明显升高，而血清中水平不高。
我们的研究结果表明，CSF 中外泌体和外泌体 miR-15a、miR-21、miR-155、miR-210 和 miR-19b 可能是 CNSL 患者诊断的有前途的生物标志物。需要进一步的研究来证实我们的发现。
